Risk factor
Very poor trading liquidity
Profitability factor
Favourable price performance
About
Headquartered in Mumbai, India, and established in 1981, NGL Fine-Chem Limited operates as a worldwide producer and distributor of pharmaceutical ingredients and intermediates for both veterinary and human health sectors. The company's comprehensive portfolio of active pharmaceutical ingredients (APIs) for animal applications features substances like diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine HCl, S-methoprene, praziquantel, toltrazuril, decoquinate, flunixin meglumine, carprofen, fenbendazole, amitraz, and marbofloxacin. For human therapeutic use, they supply APIs including nitazoxanide, atovaquone, and ranolazine. Furthermore, NGL Fine-Chem manufactures various intermediate compounds and offers completed pharmaceutical formulations in both granule and tablet formats.
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.